Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 2
2013 1
2014 2
2015 2
2016 4
2017 5
2018 4
2019 1
2020 3
2021 3
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy.
Sjögreen-Gleisner K, Flux G, Bacher K, Chiesa C, de Nijs R, Kagadis GC, Lima T, Georgosopoulou ML, Gabiña PM, Nekolla S, Peters S, Santos J, Sattler B, Stokke C, Tran-Gia J, Gilligan P, Bardiès M. Sjögreen-Gleisner K, et al. Phys Med. 2023 Dec;116:103166. doi: 10.1016/j.ejmp.2023.103166. Epub 2023 Nov 4. Phys Med. 2023. PMID: 37926641 Free article. Review.
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.
Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Bacher K, Eberlein U, Visser EP, Chouin N, Ljungberg M, Bardiès M, Lassmann M, Strigari L, Konijnenberg MW. Chiesa C, et al. Among authors: sjogreen gleisner k. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1783-1786. doi: 10.1007/s00259-017-3707-3. Epub 2017 May 24. Eur J Nucl Med Mol Imaging. 2017. PMID: 28536834 No abstract available.
Averaging of absorbed doses: How matter matters.
Gustafsson J, Ljungberg M, Alm Carlsson G, Larsson E, Warfvinge CF, Asp P, Sjögreen Gleisner K. Gustafsson J, et al. Among authors: sjogreen gleisner k. Med Phys. 2023 Oct;50(10):6600-6613. doi: 10.1002/mp.16528. Epub 2023 Jun 5. Med Phys. 2023. PMID: 37272586 Free article.
Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.
Sundlöv A, Sjögreen-Gleisner K, Tennvall J, Dahl L, Svensson J, Åkesson A, Bernhardt P, Lindgren O. Sundlöv A, et al. Among authors: sjogreen gleisner k. Neuroendocrinology. 2021;111(4):344-353. doi: 10.1159/000507761. Epub 2020 Apr 8. Neuroendocrinology. 2021. PMID: 32259830 Free PMC article. Clinical Trial.
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.
Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. Sjögreen Gleisner K, et al. Eur J Nucl Med Mol Imaging. 2022 May;49(6):1778-1809. doi: 10.1007/s00259-022-05727-7. Epub 2022 Mar 14. Eur J Nucl Med Mol Imaging. 2022. PMID: 35284969 Free PMC article.
35 results